Can a new pill change the Brain's activity in early Alzheimer's?
NCT ID NCT07768592
First seen Aug 17, 2026 · Last updated Aug 17, 2026
Summary
This early-stage trial is testing an experimental oral drug called E2511 in people with early Alzheimer's disease, including those with mild cognitive impairment or mild dementia. The study aims to see if E2511 affects a specific brain signal measured by PET scans, and to check its safety and tolerability over time. Participants first receive either E2511 or donepezil (a standard Alzheimer's medication), then all may continue on E2511 for up to 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- E2511 oral tablets
- What this could lead to
- If E2511 works, it could offer a new way to slow or alter the course of early Alzheimer's disease.
- What could go wrong
- This is an early, small study focused on safety and how the drug works in the body, not proof it helps symptoms. Long-term effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMERS DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Real-World data uncover hidden risks of the Alzheimer's drug LEQEMBI?
- Could a diabetes drug tame Alzheimer's inflammation?
- Nasal spray could tame brain inflammation in early Alzheimer's
- New drug aims to stop Alzheimer's before it starts in gene carriers
- Scientists hunt for molecular proof that music helps Alzheimer's patients
- Blood test aimed to speed up Alzheimer's diagnosis, but study was canceled